Back to Journals » OncoTargets and Therapy » Volume 8

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib

Authors Zhang Y, Tang H, Li J, Li M

Received 9 December 2014

Accepted for publication 15 April 2015

Published 8 June 2015 Volume 2015:8 Pages 1351—1354

DOI https://doi.org/10.2147/OTT.S78925

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Professor Daniele Santini


Ying Zhang, Huaping Tang, Jun Li, Meng Li

Department of Respiration Medicine, Municipal Hospital, Qingdao, People’s Republic of China

Abstract: Lung cancer has the highest mortality rate of all cancers world­wide. A total of 70%–75% of all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with locally advanced or metastatic disease at diagnosis. Brain metastasis is one of the most common problems in the management of NSCLC, worsening the prognosis and quality of life of NSCLC patients. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. Icotinib is a new type of oral EGFR-TKI. In this report, we describe a patient with lung adenocarcinoma cancer with brain metastases who received icotinib treatment and kept satisfactory health-related quality of life for 1 year.

Keywords: EGFR, non-small cell lung cancer, tyrosine kinase inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]